Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

The prevalence of frailty was 33% among a US-wide cohort of patients with RMDs, with the highest rates found among those with fibromyalgia or CTDs.

The FDA has issued a CRL to Replimmune regarding the BLA for vusolimogene oderparepvec (RP1) in combination with nivolumab for advanced melanoma.

The HHS is directing the Organ Procurement and Transplantation Network to implement new safety measures following accusations of negligence.